November 24, 2016 - By Michael Collier
In an analyst note sent to clients and investors on 24 November, Futura Medical PLC (LON:FUM) stock had its Corporate Rating reiterated by investment analysts at N+1 Singer.
About 217,400 shares traded hands. Futura Medical plc. (LON:FUM) has risen 203.85% since April 25, 2016 and is uptrending. It has outperformed by 198.44% the S&P500.
Futura Medical plc is a United Kingdom pharmaceutical firm that develops products for consumer healthcare. The company has a market cap of 63.25 million GBP. The Firm is engaged in the research and development of pharmaceutical drugs and medical devices and the commercial exploitation. It currently has negative earnings. It is also engaged in transdermal delivery and has developed a transdermal technology, DermaSys for the absorption of active molecules through the skin.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.